A Phase 1b study of chemotherapy and two novel triplets belrestotug with dostarlimab and anti-PVRIG antibody
Latest Information Update: 11 Aug 2023
At a glance
- Drugs Antineoplastics (Primary) ; Belrestotug (Primary) ; Dostarlimab (Primary) ; GSK 4381562 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
Most Recent Events
- 11 Aug 2023 New trial record